These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

341 related items for PubMed ID: 28540646

  • 1. The Molecular Mechanism of Glucagon-Like Peptide-1 Therapy in Alzheimer's Disease, Based on a Mechanistic Target of Rapamycin Pathway.
    Li L.
    CNS Drugs; 2017 Jul; 31(7):535-549. PubMed ID: 28540646
    [Abstract] [Full Text] [Related]

  • 2. Targeting amyloid-beta by glucagon-like peptide -1 (GLP-1) in Alzheimer's disease and diabetes.
    Bak AM, Egefjord L, Gejl M, Steffensen C, Stecher CW, Smidt K, Brock B, Rungby J.
    Expert Opin Ther Targets; 2011 Oct; 15(10):1153-62. PubMed ID: 21749267
    [Abstract] [Full Text] [Related]

  • 3. [Glucagon-like peptide 1: a novel therapeutic strategy for Alzheimer's disease].
    Wang XH, Yang W, Qi JS.
    Sheng Li Xue Bao; 2010 Oct 25; 62(5):398-406. PubMed ID: 20945041
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic potential of spinal GLP-1 receptor signaling.
    Zhang D, Lv G.
    Peptides; 2018 Mar 25; 101():89-94. PubMed ID: 29329976
    [Abstract] [Full Text] [Related]

  • 5. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease.
    Hölscher C.
    Biochem Soc Trans; 2011 Aug 25; 39(4):891-7. PubMed ID: 21787319
    [Abstract] [Full Text] [Related]

  • 6. Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease?
    Li L.
    Neurosci Bull; 2007 Jan 25; 23(1):58-65. PubMed ID: 17592527
    [Abstract] [Full Text] [Related]

  • 7. Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration.
    Duarte AI, Candeias E, Correia SC, Santos RX, Carvalho C, Cardoso S, Plácido A, Santos MS, Oliveira CR, Moreira PI.
    Biochim Biophys Acta; 2013 Apr 25; 1832(4):527-41. PubMed ID: 23314196
    [Abstract] [Full Text] [Related]

  • 8. Novel GLP-1 (Glucagon-Like Peptide-1) Analogues and Insulin in the Treatment for Alzheimer's Disease and Other Neurodegenerative Diseases.
    Calsolaro V, Edison P.
    CNS Drugs; 2015 Dec 25; 29(12):1023-39. PubMed ID: 26666230
    [Abstract] [Full Text] [Related]

  • 9. GLP-1 analogue improves hepatic lipid accumulation by inducing autophagy via AMPK/mTOR pathway.
    He Q, Sha S, Sun L, Zhang J, Dong M.
    Biochem Biophys Res Commun; 2016 Aug 05; 476(4):196-203. PubMed ID: 27208776
    [Abstract] [Full Text] [Related]

  • 10. Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer's and Parkinson's Diseases.
    Batista AF, Bodart-Santos V, De Felice FG, Ferreira ST.
    CNS Drugs; 2019 Mar 05; 33(3):209-223. PubMed ID: 30511349
    [Abstract] [Full Text] [Related]

  • 11. Comorbidity Analysis between Alzheimer's Disease and Type 2 Diabetes Mellitus (T2DM) Based on Shared Pathways and the Role of T2DM Drugs.
    Karki R, Kodamullil AT, Hofmann-Apitius M.
    J Alzheimers Dis; 2017 Mar 05; 60(2):721-731. PubMed ID: 28922161
    [Abstract] [Full Text] [Related]

  • 12. The Triangle of Death in Alzheimer's Disease Brain: The Aberrant Cross-Talk Among Energy Metabolism, Mammalian Target of Rapamycin Signaling, and Protein Homeostasis Revealed by Redox Proteomics.
    Di Domenico F, Barone E, Perluigi M, Butterfield DA.
    Antioxid Redox Signal; 2017 Mar 10; 26(8):364-387. PubMed ID: 27626216
    [Abstract] [Full Text] [Related]

  • 13. Glucagon-like peptide-1 analog-mediated protection against cholesterol-induced apoptosis via mammalian target of rapamycin activation in pancreatic βTC-6 cells -1mTORβTC-6.
    Zhou J, Wu J, Zheng F, Jin M, Li H.
    J Diabetes; 2015 Mar 10; 7(2):231-9. PubMed ID: 24909811
    [Abstract] [Full Text] [Related]

  • 14. Anti-autophagic and anti-apoptotic effects of memantine in a SH-SY5Y cell model of Alzheimer's disease via mammalian target of rapamycin-dependent and -independent pathways.
    Song G, Li Y, Lin L, Cao Y.
    Mol Med Rep; 2015 Nov 10; 12(5):7615-22. PubMed ID: 26459718
    [Abstract] [Full Text] [Related]

  • 15. Glucagon like peptide-1 (GLP-1) likes Alzheimer's disease.
    Yildirim Simsir I, Soyaltin UE, Cetinkalp S.
    Diabetes Metab Syndr; 2018 May 10; 12(3):469-475. PubMed ID: 29598932
    [Abstract] [Full Text] [Related]

  • 16. PI3-kinase/Akt/mTOR signaling: impaired on/off switches in aging, cognitive decline and Alzheimer's disease.
    O' Neill C.
    Exp Gerontol; 2013 Jul 10; 48(7):647-53. PubMed ID: 23470275
    [Abstract] [Full Text] [Related]

  • 17. mTOR-dependent TFEB activation and TFEB overexpression enhance autophagy-lysosome pathway and ameliorate Alzheimer's disease-like pathology in diabetic encephalopathy.
    Cheng L, Chen Y, Guo D, Zhong Y, Li W, Lin Y, Miao Y.
    Cell Commun Signal; 2023 May 04; 21(1):91. PubMed ID: 37143104
    [Abstract] [Full Text] [Related]

  • 18. The human glucagon-like peptide-1 analogue liraglutide regulates pancreatic beta-cell proliferation and apoptosis via an AMPK/mTOR/P70S6K signaling pathway.
    Miao XY, Gu ZY, Liu P, Hu Y, Li L, Gong YP, Shu H, Liu Y, Li CL.
    Peptides; 2013 Jan 04; 39():71-9. PubMed ID: 23116613
    [Abstract] [Full Text] [Related]

  • 19. Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.
    McClean PL, Hölscher C.
    Neuropharmacology; 2014 Jan 04; 76 Pt A():57-67. PubMed ID: 23973293
    [Abstract] [Full Text] [Related]

  • 20. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies.
    Chen Z, Zhong C.
    Prog Neurobiol; 2013 Sep 04; 108():21-43. PubMed ID: 23850509
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.